Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Bamlanivimab is authorized for patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kilograms (about 88 pounds), and who are at high risk for progressing to severe COVID-19 and/or hospitalization. This includes those who are 65 years of age or older, or who have certain chronic medical conditions.Continue reading

Final Steel Beam Tops Off The Refinery Building at the UA Tech Park at The Bridges 

 

TUCSON, Ariz.–  The steel frame and concrete floors are coming to completion at The Refinery. The final beam of The Refinery was placed, topping off the steel framework for the 120,000 square foot structure.  The Refinery is the kickoff building to the new UA Tech Park at The Bridges, an extension campus birthed from the success of the UA Tech Park near Interstate 10 and Rita Road.  Continue reading

Are COVID-19 Vaccines Safe and Effective?

COVID-19 Vaccines are viewed as the light at the end of the tunnel.  We are not there yet but we will get there.  Hundreds of millions of people in the United States and billions of people globally will need to be immunized against COVID-19.  But, are these vaccines safe and effective?  Would you recommend that someone you love get one?

Continue reading

Thousands of Arizonans to Contribute to 2-Year COVID-19 Study

Actively recruiting —

A cross-campus collaboration spearheaded by the College of Public Health seeks to understand ‘long COVID’ and other coronavirus mysteries.

After more than a year since its earliest documented appearance, much remains unknown about SARS-CoV-2. The lack of actionable data about the novel coronavirus, which threw the world into a pandemic, has prompted the University of Arizona Health Sciences to undertake the first statewide long-term public health study of COVID-19: the Arizona CoVHORT study. The research effort is intended to shed light on infection risk and the recovery process to improve care for patients touched by this crisis.

Continue reading

Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released

An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months.Continue reading